WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 17, 627-649. Review Article ISSN 2277–7105

ARTIFICIAL INTELLIGENCE AND NANOPOLYMERS: BRIDGING PREDICTIVE MODELING WITH EXPERIMENTAL DISCOVERY

Bindu Rathore[1], Mahendra Sharma*[2], Satendra Tiwari[3], Megha Nigam[4], Sachin Dangi[5], Sumit Kumar[6]

[1]Department of Pharmaceutical Chemistry, SBS Daddu Ji College of Pharmacy, Major SD Singh University, Bhojpur, Kanpur Road Fatehgarh Farrukhabad (UP), India.
[2*]Department of Pharmaceutics, SBS Daddu Ji College of Pharmacy, Major SD Singh University, Bhojpur, Kanpur Road Fatehgarh Farrukhabad (UP), India.
[3]Department of Pharmaceutics, Dr Anar Singh College of Pharmacy, Major SD Singh University, Bhojpur, Kanpur Road Fatehgarh Farrukhabad (UP), India.
[4]Department of Pharmacognosy, SBS Daddu Ji College of Pharmacy, Major SD Singh University, Bhojpur, Kanpur Road Fatehgarh Farrukhabad (UP), India, 209749.
[5]Department of Pharmacology, SBS Daddu Ji College of Pharmacy, Major SD Singh University, Bhojpur, Kanpur Road Fatehgarh Farrukhabad (UP), India, 209749.
[6]Department of Pharmacology, Dr Anita Yadav College of Pharmacy, Major SD Singh University, Bhojpur, Kanpur Road Fatehgarh Farrukhabad (UP), India, 209749.

Article Received on
17 July 2025,
Revised on 06 August 2025,
Accepted on 26 August 2025
DOI: 10.20959/wjpr202517-38173

***Corresponding Author**
Mahendra Sharma
Department of Pharmaceutics, SBS Daddu Ji College of Pharmacy, Major SD Singh University, Bhojpur, Kanpur Road Fatehgarh Farrukhabad (UP), India.

ABSTRACT

Artificial Intelligence (AI) and nanopolymers are moving towards a revolutionary paradigm that interconnects predictive modeling with experimental discovery. Tunable properties, biodegradability, and stimuli responsiveness Filtered to include only important concepts, nanopolymers, which have emerged as next-generation drug delivery and biomedical vehicles, can be used because of their variable characteristics, biodegradability, and stimuli responsiveness. The complexity of polymer drug interactions, nonhomogeneous patient response, and inabilities of preclinical translation, however, require sophisticated computational packages. To discover innovative functional molecules and compounds, AI has become a potent force in polymer science with the potential to forecast or predict polymer properties, or optimize the design of nanocarriers as well as shortening the discovery cycle. Quantum computing, machine learning (ML), and swarm intelligence-based methods enable the analysis of polymers to be rapidly screened, toxicity to be predicted, and nanocarriers can be rationally designed. Predictive modeling using AI with experimental studies like that of molecular dynamics simulations, and high-throughput screening lowers the cost and wasted time in the nanomedicine development process. In this review, the developements at the interface of AI and nanopolymers in predictive design of nanopolymers nanocarriers, analysis of compatibility between drugs and nanopolymers, regulatory issues and ethical considerations are discussed. Moreover, it emphasizes the concept that with experimental confirmation, and AI-based modeling a synergistic feedback loop can be established to catalyze innovation in drug delivery, personalized medicine, and smart therapeutic platforms. Finally, we summarize by listing the directions in the future that the hybrid AI-experimental framework with transparency made possible by blockchains and quantum-aided simulated may transform the polymer research and translational nanomedicine fields.

KEYWORDS: Artificial intelligence, nanopolymers, predictive modeling, drug delivery, molecular dynamics, smart materials, biomedical applications, experimental discovery.

1. INTRODUCTION

Nanopolymers have become one of the most diverse of material groups in modern therapeutics. They have structural flexibility, biocompatibility, are capable to encapsulate a variety of therapeutic agents, which allows them to resolve some disadvantages of conventional formulations.[1] In contrast to small molecules or bulk polymers, nanopolymeric systems can be designed in a way to adjust release kinetics, enhance solubility and safeguard drugs against premature degradation.[2] These properties render them particularly well suited to chronic disorders like inflammatory bowel disease where active manipulation of the microbiome has already proved therapeutically relevant using complexes and probiotics complexes as well as prebiotics.[1]

The delivery of nanopolymers is not restricted to oral or injectable means. They have been incorporated in the last several years into hydrogels, micelles, nanocapsules and implantable devices, which enabled the development of intelligent delivery systems that can trace the environmental stimuli.[3] To mention one example, inulin is a natural biopolymer that has been redesigned as multifunctional nanocarriers, with the capability to deliver the targeted cells, being immunomodulatory or increasing the stability of bioactive molecules.[3] These advances have shown the movement towards heavily engineered nano structured systems with tailorable curative capacity replacing conventional polymers.

1.2 Limitations of Conventional Development Approaches

Although a prospective, inherent complexity of polymer drug interactions and the large material variables design space impedes development of nanopolymeric carrier-based technology development.[2] Traditional trial-and-error methods can involve time consuming synthesis, time consuming characterization, and time consuming optimization. Not only does this extend development schedules, but it makes development even more expensive, hindering the process of taking innovative materials into clinical practice.[4]

Automation in robotics is starting to overcome some of these bottlenecks by speeding up the rate of experiment and reducing human error.[4] Automation offers the possibility to incorporate data collection in the real time into the research pipelines, making them fast to iterate and reproduce. Nevertheless, the volume and heterogeneity of generated data are overwhelming to achieve and extract the actionable insight with basic computational techniques.[5]

1.3 Emergence of Artificial Intelligence in Material Discovery

Artificial intelligence (AI) has observed in pharmaceutical and biomedical research a growing significance attached to it due to its capacity to handle, manage, and detect latent trends and create forecasts.[5] On the one hand, for the purposes of polymer science, AI has been used to streamline methods of synthesis and estimates of physicochemical behaviour as well as estimates of the biological performance of nanocarriers.[2]

More broadly, AI coupled with the Internet of Things (IoT) and big data have been shown to have the ability to not only manage complex systems, but also identify valuable relationships that would otherwise go unidentified.[5] These skills can be directly applied to the study of nanopolymers, where parameters such as polymer composition, drug-loading, particle size and release mechanisms are multifactorial to an extent that they interact non-linearly with each other. With the help of AI, researchers will be able to get less dependent on the empirical screening and focus experimental validation of the most likely candidates.[6]

1.4 Bridging Predictive Modeling with Experimental Discovery

The combination of AI and nanopolymers suggested the possibility of synergistic workflow between predictive modeling and experimental design and vice versa.[6] To illustrate, with regards to biomedical applications, newer works within the context of nanomaterial-driven AI reveal how polymer stability, toxicity, and therapeutic efficacy can be predicted in a machine learning model prior to synthesis in a laboratory.[6] Not only does the said integration speed up research, but also minimizes the waste of research materials and the ethical implications of original excessive in vivo experimentations.

Nanotechnology with AI guidance has special potential in healthcare with regard to cancer, neurodegenerative disorders, and infectious diseases. With predictive algorithms combined with nanoscale engineering, it can be envisioned that patient-specific therapy can then be designed to best optimize the therapy and minimize side-effects.[7] But to achieve this potential demands feedback loops that are strong enough to subject computational predictions to never-ending verification and refinement by high-quality experimental data.

1.5 Scope of the Review

It is in this context that this review seeks to dwell on the convergence between artificial intelligence and nanopolymer science, and the extent to which predictive modelling and experimental discovery can be made to work hand in hand to enhance the rate of material innovation. We start with the progress in the AI applications in polymer research, and then the trendy experimental approaches in nanopolymer engineering will be discussed. Advanced areas then set out the predictive-experimental feedback loops, regulatory and ethical issues, and outlooks on AI-facilitated nanopolymer discovery in the future. This review will look at computational and experimental aspects to provide a comprehensive overview of the ways in which AI promises to revolutionize nanopolymers as the basis of next-generation biomedical therapies.

2. ARTIFICIAL INTELLIGENCE IN POLYMER SCIENCE

2.1 Expanding the Role of AI in Healthcare and Pharmaceuticals

The application of artificial intelligence has moved consistently eschews to companionship in the exploratory data analysis towards the core companionship of breakthrough and discovery in the healthcare industry.[8] The use of AI-driven algorithms in pharmaceutical science has already seen new drug candidate design, pharmacokinetic modeling and more efficient drug repurposing. This flexibility means that AI can be applied to very differently formatted data sets, including molecular descriptors, clinical trial results, and so, occupies the gap between laboratory research and translational medicine.[9]

In the field of oncology, such as, AI resources were effectively deployed in the setting of the diagnostic and prognostic frameworks, increasing the accuracy of such settings and establishing the opportunity to personalize the treatment regimen in a data-driven way.[10] These developments demonstrate the enormous promise of AI to transform drug discovery and delivery in this case, the design of nanopolymer-based carriers.

2.2 Predictive Modeling in Polymer Science

In polymer research, predictive modeling using AI has become an increasingly popular method of screening challenges, presenting a potentially effective replacement of traditional experimental methods. Advanced algorithms, like machine learning (ML) and deep learning methods, are capable of making predictions concerning all-important aspects of polymers solubility, the rate at which they release drugs, their biodegradation rates, and toxicity.[11] These models have the capacity to quickly evaluate the effects of structural variations on functionality, given that they can use computational power; this allows the researchers to eliminate the less promising candidates at an early stage, therefore focusing on the most promising ones.

Notably, even reproducibility which is another necessity in the translation of nanopolymeric systems into clinics is enhanced in predictive methods. The use of statistical as well as AI-based tools minimizes the variability in data by determining influential parameters of the experiments that determine the performance.[12]

2.3 AI in Optimization of Nanopolymer Design

Among the most potentially paradigm-altering applications of AI is the optimisation of nanopolymers systems as drug delivery. Multi-criteria decision-making frameworks and AI-supported algorithms are only some of the techniques that enable a researcher to compare the design variables in question.[12] This is demonstrated by way of example, where, in the layering of polymeric nanoparticles, the drug loading efficiency, particle size, surface charge, and kinetics of release can be fine-tuned simultaneously and not one against another. This minimises trial and error loop and quickens the route to clinically viable preparations.

In addition to that, the AI tools help to maneuver tradeoffs among various performance features. Even a polymerification system optimized to load the maximum amount of drug can unintentionally destabilized release or reduced bio-compatibility. These trade-offs are more systematic with AI-based optimization and yields balanced solutions that fulfill therapeutic objectives.[13]

2.4 Integration with Biomaterial Innovation

AI-supported polymer science does not only involve conventional drug carriers but also any new biomaterials, e.g., stimuli-responsive polymers, hydrogels, and multifunctional nanocarriers.[13] These sophisticated systems can be characterized to have dynamic behavior that is a characteristic of response to pH, temperature, or the presence of enzymatic activities, dynamic behavior that is complex to model conventionally using mathematical methods. The use of AI makes it possible to efficiently model such non-linear interactions at very high fidelity and to rationally design so-called intelligent biomaterials.

The merging of AI and polymer will also follow trends of personalized medicine. Since patients are not a homogenous group, the possibility of tailoring nanopolymers with regard to patients and individual therapeutic applications, is possible by including patient-specific data in the design pipelines.[14] The strategy has been especially useful in cancer treatment, in which tumors may vary widely due towhich personalized drug delivery methods are required.

2.5 Outlook on AI for Polymer Research

The introduction of AI to polymer science introduces a paradigm shift in the direction of data-driven precision-guided innovation. With the help of predictive modeling, optimization algorithms, and insights on a patient-specific level, researchers should address long-standing issues in nanopolymer design. Although there are still certain technical obstacles to overcome (standardizing datasets, intelligible algorithms, among others), the outlook of polymer research with the help of AI is certainly revolutionary. Figure 1 is Evolution of polymers in drug delivery systems, which follows the trending of the biodegradable polymers approach, followed by a stimuli-responsive system, AI-enabled polymers and finally the intelligent carrier. Such a conceptual drawing shows the evolution of polymer-based platforms towards sophistication.



Figure 1: Evolution of polymers from Biodegradable to intelligent carrier.

3. APPLICATIONS OF AI-DRIVEN NANOPOLYMERS IN NANOMEDICINE

3.1 Targeted Drug Delivery

There is a long history of appreciating nanopolymers as an option to improve delivery of therapeutic agents, especially in the context of anticancer and infectious disease therapy.[15] Their low volumes, bio-compatibility, and capability to entrap both hydrophobic and hydrophilic medications enable them to overcome biological boundaries, elongate upsurge times and ability to liberate medication regulated conveyance. Computer-aided rational design of these carriers is currently being expedited through the use of AI to forecast drugpolymer compatibility and then optimizing formulation variables.[16]]

With data-driven modeling, AI can be used to model how given polymer architectures interact with drugs at the molecular level, helping researchers to reduce the trial-and-error element of experiments.[17] Such ability to predict has played a critical role in the development of polymeric nanoparticles to be used in targeted therapy where the efficacy and safety need a high degree of balancing.

3.2 Gene and Protein Delivery

In addition to the small-molecule drugs, nanopolymers have also demonstrated to be highly promising in terms of nucleic acid and protein delivery medium.[18] Nonetheless, these systems are associated with problems such as instabilities in biological fluids, immunogenicity and unpredictable intracellular uptake. The limitations can be mitigated through AI-driven methods that allow modeling carrier-to-cargo interactions and provide stable profile predictions on various physiological conditions.[19]

As an illustration, examples of analysis could be performed on a dataset of polymer-based delivery structures, and their performance in transfection or protein stabilization in order to find pattern associations with any effective performance.[20] This hastens the engineering of nanopolymers which are more favorable in gene therapy, RNA therapeutics as well as delivery of proteins in precision medicine.

3.3 Cancer Therapy Applications

In oncology, AI-amplified nanopolymer systems have been one of the oldest applications. Some common problems of the traditional chemotherapy include occurrence of systemic toxicity, multidrug resistance and unfavorable bioavailability.[2] AI-assisted design of polymeric nanocarriers with fine control over release kinetics to achieve tumor-targeted delivery and minimize systemic exposure, maximizing therapeutic payload delivery is possible.[21]

Integrating the individualization of tumor biology data with an AI-optimized polymer system will enable tailored cancer nanomedicine. Such strategies would allow finding the optimal carrier design in relation to a particular patient, which will enhance the rate of responses and minimize the negative effects.

3.4 AI-Enabled Personalization

One of the unique opportunities of applying AI to nanopolymers research is that the former will allow the implementation of personalized medicine.[21] The selection of nanopolymer formulations could be directed by patient-derived information, e.g. genomic profile learning, proteomic markers, and disease phenotype.

This makes sure that therapeutic interventions can be disease-specific and specific to patients. As an example, in breast cancer or glioblastoma, with their high-inter-patient variability that strongly affects the drug response, the AI-guided nanopolymer could be adjusted to the tumor microenvironment. The ability demonstrates the innovative linkage of the fields of AI, polymer science, and precision medicine.

3.5 Outlook

The introduction of AI to the use of nanopolymers in nanomedicine has already evinced significant potential, in drug delivery, gene therapy, and cancer treatment. Nonetheless, to transfer these accomplishments to everyday clinical practice, it will be necessary to have consistent data models, shared platforms, and meticulous regulatory supervision [21]. Taking this into consideration, AI-based nanopolymers can become a solution of a new generation that will be able to match the unmet medical needs. Table 1 Comparative overview of representative polymers used on a nanocarriers framework, with examples of biodegradability, physical-chemical properties and biomedical applications.

Table 1: Representative polymers used in nanocarrier systems: properties, biodegradability, and biomedical applications.

Polymer Type	Examples	Biodegradability	Key Properties	Biomedical Applications	References
Natural Polymers	Chitosan, Alginate, Hyaluronic acid	High (enzymatic degradation)	Biocompatible, mucoadhesive, hydrophilic	Gene delivery, wound healing, mucosal drug delivery	[3, 7]
Synthetic Biodegradable Polymers	PLGA, PCL, PLA	Moderate to High (hydrolytic degradation)	Tunable degradation, FDA-approved, versatile	Cancer therapy, vaccine delivery, tissue regeneration	[10, 12]
Stimuli-Responsive Polymers	Eudragit®, Poly(N-isopropylacrylamide), PEGylated copolymers	Variable	pH- or temperature-sensitive, smart release	Oral colon-specific delivery, hyperthermia-based drug release	[16, 18]
Intelligent Polymers (AI-Designed/Adaptive)	PEG-PCL-PEG copolymers, dendrimer hybrids	Moderate	Self-assembling, predictive performance via AI algorithms	Personalized drug release, theranostics, biosensing	[28, 41]
Green/Eco-Polymers	Cellulose derivatives, starch-based polymers	High (renewable, enzymatic degradation)	Sustainable, low toxicity	Eco-friendly nanocarriers, food–drug interface	

4. AI AND PREDICTIVE TOXICOLOGY OF NANOPOLYMERS

4.1 Importance of Nanotoxicology

Although nanopolymers promise tremendous potential in biomedical areas, they have complex interfacial interactions with biological systems which cloud issues of safety.[22] Toxicity can also occur as a result of polymer by-products of degradation, accumulation of nanoparticles in the organs or unexpected immune responses. Due to the advancing field of nanomedicine, it is important to assess the associated risks to make sure the therapeutic formulations are effective, and safe. Conventional toxicological evaluations are resource intensive, time consuming and can have short predictive efficacy.[23]

4.2 AI-Driven Predictive Models

AI has become one of the game-changing technologies in predictive toxicology as it can make data-driven, fast, and precise toxicity predictions.[23] Machine learning models have capabilities to analyze complicated data linked to the physicochemical properties, biological interactions, and in vitro or in vivo outcomes and predict toxicity profiles of nanopolymers. These models can offer good leads on impending dangers and offer safe design specifications before testing an idea in people.[24]

Pre-clinical models that rely on the use of these AI-driven predictive tools are especially beneficial in the evaluation of toxicity data, including cytotoxicity, genotoxicity, oxidative stress, and immunotoxicity. The potential of AI to reduce the necessity of carrying out appropriate animal studies mitigates the time limitations on the research pipeline, as well as adheres to ethical considerations of minimizing animal testing.[24]

4.3 High-Throughput Screening and Data Integration

The cell interactions, uptake, and toxicity of nanoparticles are explored in high via high throughput screening (HTS) technologies which produce large volumes of data.[25] Combining HTS outputs with AI frameworks enables researchers to find the trends and correlations that they would otherwise have missed. Creative AI models have the ability to synthesize big data into predictive toxicity-mapping options and direct the choice of nanopolymers with incompatible safety profiles.

An example is the ability to clear the difference between toxic and non-toxic nanopolymer formulations fairly accurately using classification algorithms.[26] Such predictive information cuts down on trial-and-error and reproducibility, where nanopolymer platforms are effective and biocompatible.

4.4 Regulatory Relevance of AI in Toxicology

Regulatory-wise, AI-assisted predictive toxicology will allow the process of risk assessment to become much more streamlined. The importance of predictive, mechanism-based assessments is gaining weight in regulatory agencies, instead of only expository toxicology.[26] Artificial intelligence-based models aids in the standardization of toxicity prediction, giving replicable models, which may be adapted to preclinical validation and acceptance.

Moreover, AI-enhanced predictive toxicology can pre-empt underlying in vivo risks at an early phase, in turn reducing the risk of clinical trial failures during later stages.[27] It saves not only money but also dangers of the development of nanopolymer, and it is more effective to transfer polymer-based therapeutics into practice.

4.5 Future Prospects

Nanopolymer toxicology is an important step in the overall field of safe and accountable innovation by integrating AI technology. AI algorithms will only grow stronger in predicting toxicity across the range of nanopolymer systems as more complete data sets become available.[27] Beyond this, a combination of AI and mechanistic modeling could provide a way to deconstruct the biological mechanisms underneath adverse effects, providing both mechanistic insight and predictive capability.

Finally, AI-driven predictive toxicology will likely strike the balance between innovation and safety, by making sure that innovative nanopolymer design not only works, but also lacks harmfulness to be bio-compatible and translate into clinical practice.

5. INTELLIGENT POLYMERS AND SMART NANOCARRIERS

5.1 Concept of Intelligent Polymers

Smart, or intelligent, polymers are novel materials, which aim at reacting to a certain physiological or environmental stimuli like pH, temperature, enzymes, redox or light.[28] They are dynamic in their responsiveness and therefore very appealing in biomedical responses where the controlled release, specific action and reduced side effect are critical. This combination of artificial intelligence with the design of these materials allows studying, (predicting) the structural characteristics that improve contact with stimuli, fully optimizing it to be useful in clinical practice.[29]

5.2 Stimuli-Responsive Nanocarriers

The intelligent polymers have potential stimuli-responsive nanocarriers applied in site-specific drug delivery. As an example, pH-sensitive systems surge the anticancer drugs in an acidic tumor environment, and thermo-sensitive carriers can be evoked under slight hyperthermia.[30] The recent use of AI models has seen a faster solution to discovering such a system because what they do is simulate a polymer drug correlation under different conditions, and by doing so it is possible to find the fastest solution that is able to release drugs accurately at the target location of choice.

Such systems prefigure the promise of precision medicine because they (1) lessen off-target effects and (2) improve therapeutic efficiency. They can also be multi-stimuli responsive, wherein two or more signals (e.g. pH and temperature) have a synergistic effect in precision of drug release profiles.[30] Figure 2 shows the significant previous and internal stimuli such as pH, temperature, redox potential, enzyme activity, light and magnetic fields, which make it possible to perform site-specific and on demand delivery of therapeutic agents.



Figure 2: Mechanisms of stimuli-responsive nanocarriers for controlled drug release.

5.3 Role of AI in Smart Nanocarrier Optimization

AI-based methods are very influential in smart nanocarrier optimization.[31] Parameters that machine learning models can be employed to predict in terms of drugs loading efficiency, release kinetics, and stability include polymer molecular weight, degree of cross-linking and hydrophobic/hydrophilic balance. Identification of those formulations likely to be successful in the clinic in these predictive insights.

In addition, using AI will support in silico experimentation, where hundreds of potential polymeric formulations could be screened computationally followed by the selection of the most promising candidates to be subjected to laboratory-based validation. The approach minimizes the costs of the experimentation and hastens drug development schedules.[31]

5.4 Smart Carriers for Combination Therapy

A new field is smart nanocarriers that can co-deliver multiple therapy agents including chemotherapeutic agents and gene silencing agents.[32] The use of intelligent polymers makes sequential release or simultaneous release possible, which are customized to the method of disease progression. Artificial intelligence (AI) tools are able to simulate such complicated release dynamics, so that drug mixtures are synergistic and not antagonistic.

Multifunctional systems like this could be especially promising in oncology, where therapeutic combinations become more and more important as they attempt to break multidrug resistance and tumor heterogeneity in responses.[32]

5.5 Future Perspectives in Intelligent Polymers

The interface between intelligent polymer science and AI can be seen as a paradigm change in nanomedicine.[33] This is likely to be followed by self-adaptive polymers which would respond on a real-time basis to the varying disease environment. Further adaptability may be achieved with AI processing of patient feed-back data to allow nanocarriers that are in a continuous learning mode and adjust to patient-specific disease dynamics.

In the long run, smart AI-based nanopolymers can perhaps progress to fully autonomous medical devices, where stimuli-responsive and predictive adaptability meet, and personalized medicine can finally become a reality.[33]

6. REGULATORY CHALLENGES AND ETHICAL CONSIDERATIONS

6.1 Regulatory Complexity in Nanopolymer Development

Nanopolymer-based therapeutics have been subject to extensive regulatory challenge posed by their preeminent physicochemical and biological characteristics [34]. In contrast to conventional small-molecule drugs, nanopolymers could differ in size, chemistry and degradation so standardization is problematic. Regulatory bodies like the FDA, EMA, etc. impose strict guidelines that need safety, efficacy, and reproducibility data, which are sometimes difficult to meet using the existing structures due to fast advancements in the field of nanomedicine.[35]

6.2 Lack of Standardized Evaluation Protocols

The lack of commonly endorsed procedures to assess nanopolymer safety and performance is one of the challenges.[35] The differences in the methods used to test toxication, preclinical models and approaches to risk assessment result in conflicting data that make it difficult to obtain regulatory approval. Artificial intelligence will also offer solutions to the platforms involved in the prediction of toxicity in that, it will facilitate in harmonization of predictive toxicology frameworks in different laboratories and thus offer the standardized computational methods to determine the safety before commencing the clinical phases.[36]

6.3 Ethical Issues in Nanomedicine

In addition to regulatory systems, nanopolymers generate ethical aspects of patient autonomy, consent issues, and technology misuse.[36] Self-thinking polymers that are able to behave can behave independently in the body casting doubt over patient control of treatment. Moreover, lack of equal access to state-of-the-art nanopolymer-based therapies is likely to increase disparities in healthna. In the resource-limited setups worldwide, access to new therapies has always been limited.[37]

6.4 Data Privacy and AI in Nanomedicine

Usage of AI in nanopolymer development adds one more ethical aspect to data privacy.[37] Deep learning predictive models require the use of large datasets that include the genomics and clinical data of patients. Safe management of such sensitive information is essential to the trust of AI-enabled nanomedicine. The ethics framework should thus provide a balance on innovation and strong privacy protection and conspicuous patient confirmation.[38]

6.5 Towards Ethical and Regulatory Harmonization

To overcome these issues, a cross-stakeholder involvement approach will be involved where regulators, researchers, clinicians and ethicists participate.[38] An international alignment of nanomaterial characterization and evaluation of toxicity is in the works, and ethical regulations are also adjusting to confront the access barriers, consent issues and societal confidence as concerns. AI-powered convergence in regulatory science can facilitate this harmonization by designing transparent, reproducible and patient-centered systems of evaluation.[39] The safe, ethical, and equitable translation of nanopolymer-based therapeutics will ultimately depend on how they can be translated over the long term with societal acceptance and clinical success.

7. FUTURE DIRECTIONS AND EMERGING TRENDS

7.1 Integration of AI and Nanopolymer Platforms

The interplay of both AI and nanopolymer technologies is a growing focus of future research in regard to the production of adaptive patient-specific therapeutics.[40-46] Machine learning models have the ability to forecast polymer and drug compatibilities, optimize release profiles and personalize therapy through day-to-day patient data. This integration will enhance a faster conversion to precision medicine, characterizing nanopolymer systems to the genetic and clinical individual profile.[41,47-50]

7.2 Hybrid Nanopolymer Systems

Developing trends emphasize emerging hybrids of nanopolymer systems, where natural polymer materials are hybridized with synthetic polymer materials therefore being able to incorporate the biocompatibility with the mechanical stability.[41] These structures may have responsive characteristics, including enzyme sensitivity or redox-responsiveness without producing structural fragility. Multifunctionality can also be achieved through hybridization where a single nanocarrier can offer multiple roles, such as therapeutic and diagnostic and imaging, a step towards theranostics.[42,51-60]

7.3 Theranostic Applications

The area is shifting to nanopolymers that have therapeutic, as well as diagnostic, applications.[42, 61-63] Theranostic nanoprobes allow real-time flux of the drug, biodistribution and efficacy of therapy. The potential of AI to improve this function hinges on the ability to compare imaging data with therapeutic response to enable clinicians to modify treatment approaches in real-time.[43, 64-66]

7.4 Advances in Biodegradable and Green Polymers

Another forthcoming frontier is sustainability. Biodegradable and eco-friendly nanopolymers are being developed that reduce long term accumulation and environmental effectiveness.[43] Safer renewable polymers that do not sacrifice performance are developed using more and more green chemistry principles. The discovery of new materials led by AI provides an even faster way of developing those eco-compatible polymers, which allows green alternatives in both the healthcare sector and environment.[44]

7.5 Personalized and Adaptive Drug Delivery

The nanopolymers platforms of the future likely will be made adaptive wherein they respond continuously and dynamically to patient physiology.[44] Implementation of biosensors in combination with AI-enhanced nanocarriers can allow drug release to be adjusted on-demand depending on biomarkers, e.g. pH, glucose concentration, or inflammation. Such adaptive systems should have a chance of greatly enhancing therapeutic efficacy reducing side effects in chronic and complex diseases.[45]

7.6 Global Perspective and Accessibility

With advances in innovation, it will continue to be important to ensure equal access to advanced nanopolymers technologies around the world.[45] The problems in developing countries include the high cost, poor infrastructures, and regulatory lapse. This will also require combined initiatives of academia, industry and policymakers in a bid to exclude the likelihood of emerging technologies leaving further distance between high income and low resource areas. Machine learning-enabled cost reduction and large scale eco-friendly production could provide global implementation opportunities. This last point is illustrated in Figure 3, where the advantages of using polymers to develop nanocarriers are augmented by the incorporation of artificial intelligence (AI), which allows highly precise data-driven drug into nanocarriers, targeted drug release, and side-effect free constant monitoring of patients, eventually leading to personalized medicine.



Figure 3: AI-integrated polymer nanocarriers for personalized therapy.

8. CONCLUSION

Systems such as nanopolymers have been revolutionary drug delivery and biomedical platforms as they can be tuned, are biocompatible, and may have smart responsive capabilities. AI has also facilitated in the research of nanopolymers adding an extra edge to its design, optimization, and clinical translation leading to actual realization of personalized medicine. Along with these developments, established concerns still exist in the field of safety assessment, regulation, and access by all people worldwide. The ethical nature of such concerns as privacy of data, patient autonomy, and healthcare disparities should also be considered to allow responsible innovation. Moreover, the absence of standard testing procedures and nanopolymer-biological systems interaction complexity evidences the necessity to unify the global approach to regulation. In a forward-looking approach, flexible multifunctional nanopolymer-based systems remain the future, where all conceptual therapeutic, diagnostic, and biosensing capabilities are very well blended. They will be made even more sustainable via biodegradable and green polymers and AI-powered predictive modelling. Nanopolymers hold the promise to transform the world of contemporary therapeutics by overcoming existing regulatory and ethical obstacles and the advent of novel technologies.

DECLARATIONS

ACKNOWLEDGMENTS

The authors are highly thankful to SBS Daddu Ji College Of Pharmacy, Major SD Singh University, Bhojpur, Kanpur Road Fatehgarh Farrukhabad (UP), India for providing necessary facilities and encouragement.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

FUNDING

Not applicable.

REFERENCE

1. Sharma P, Akram W, Garud N, Tailang M. Role of Probiotics and Prebiotics in Inflammatory Bowel Disease. Inflammatory Bowel Disease and Gut Microbiota., 2025; 461-88.
2. Sharma P. Selection of an Appropriate Technique for Nano-Carrier Preparation: A Multi-Criteria Decision-Making Methodology. In Nanomedicine for Neurodegenerative Disorders Selective Treatment Strategies 2025 Feb. Apple Academic Press, Florida, USA.
3. Sharma P, Pasha TY, Aparna TN, Singaram G, Shirsat MK, Kumar V, Tiwari G. Inulin: A Versatile Polymer for Drug Delivery System. InInulin for Pharmaceutical Applications: A Versatile Biopolymer 2025 Jan 31; (pp. 53-72). Singapore: Springer Nature Singapore.
4. Bhardwaj A, Kumar SV, Vinukonda A, Ramakrishna K, Srivastava S, Rajendran SP, Sharma P. Robotics and Automation: Revolutionizing Research and Development. InEvolving Landscapes of Research and Development: Trends, Challenges, and Opportunities, 2025; 313-338. IGI Global Scientific Publishing.

5. Bhardwaj A, Bachu S, Rajendran SP, Rastogi S, Ramakrishna K, Balalakshmi C, Sharma P. The Future of Territorial Management: AI, IoT, and Big Data Synergies. InUtilizing Technology to Manage Territories, 2025; 239-272. IGI Global.
6. Chakroborty S, Nath N, Sahoo S, Singh BP, Bal T, Tiwari K, et al. A review of emerging trends in nanomaterial-driven AI for biomedical applications. *Nanoscale Adv.,* 2025; 7: 3619–30. doi: 10.1039/D5NA00032G
7. Shrestha R, Tripathi D, Hajra K, Maity D. AI and nanotechnology in modern healthcare: promises and challenges. *Front Nanotechnol.,* 2024; 6: 1298765. doi: 10.3389/fnano.2024.1298765
8. Sharma P, Rathore B, Jain S, Sharma M, Tiwari S, Kaushal R, Akram W, Jain V. Principle characteristics and specification of pharmaceutical polymers. InPolymers for Oral Drug Delivery Technologies, 2025 Jan 1; (pp. 197-231). Elsevier Science Ltd.
9. Sharma P, Dasputre N, Jain V. Nanomedicine: Concepts, Characteristics, and Regulatory Challenges. InSmart Nanocarrier for Effective Drug Delivery, (pp. 1-16). CRC Press.
10. Dierking I. A Comprehensive Review of Stimuli-Responsive Smart Polymeric Materials. *Polymers (Basel),* 2024; 16(11): 2221. doi: 10.3390/polym16112221
11. Ahmed EM. Hydrogel: Preparation, characterization, and applications: A review. *J Adv Res.,* 2015; 6(2): 105–21. doi: 10.1016/j.jare.2013.07.006
12. Rathore B, Sharma M, Tiwari S, Kaushal R, Sharma P. Advanced Nanocarriers for Nucleic Acid Delivery. InSmart Nanocarrier for Effective Drug Delivery (pp. 17-35). CRC Press.
13. Kawadkar M, Mishra P, Mishra A, Sharma P. Protein-Based Nanocarrier for Targeted Delivery of Drug for Cancer Therapy. InSmart Nanocarrier for Effective Drug Delivery, (pp. 36-60). CRC Press.
14. Sharma P, Jain V, Tailang M. How Artificial Intelligence is Transforming Medicine: The Future of Pharmaceutical Research. InIndustry 4.0 and Healthcare: Impact of Artificial Intelligence 2023 Dec 2; (pp. 133-150). Singapore: Springer Nature Singapore.
15. Sharma P. Nanostructured Biomaterials in Drug Delivery: Current Trends and Upcoming Possibilities. InEngineered Biomaterials: Synthesis and Applications 2023 Nov 27; (pp. 261-280). Singapore: Springer Nature Singapore.
16. Sharma P, Jain V, Tailang M. Advancement of Nanocarrier-Based Engineering for Specific Drug Delivery for Cancer Therapy. InTargeted Cancer Therapy in Biomedical Engineering 2023 Apr 12; (pp. 465-486). Singapore: Springer Nature Singapore.

17. Singh F, Sharma P, Akram W, Jain V. Introduction to pharmacodynamics: The basis of drug therapy. In Futuristic trends in pharmacy & nursing, IIP Proceedings 2023 Nov. 1; 24(2).
18. Polymers Editorial Team. Recent Progress of Artificial Intelligence Application in Polymer Research. *Polymers (Basel),* 2025; 17(12): 1667. doi: 10.3390/polym17121667
19. Zhang L, Zhang X, Xu J, et al. Artificial intelligence-driven prediction and design of polymeric nanocarriers for drug delivery. *Adv Drug Deliv Rev.,* 2023; 0196: 114749. doi: 10.1016/j.addr.2023.114749
20. Sharma P, Jain V, Tailang M. Role of Swarm Intelligence for Health Monitoring and Related Actions. In Internet of Things and Fog Computing-Enabled Solutions for Real-Life Challenges 2022; (pp.). CRC Press. (Accepted).
21. Bhardwaj A, Sharma B, Jain V, Jain A, Sharma P. Education. In Exploring the other half 2022; (pp. 528-542). Notion Press.
22. Sharma P, Jain V, Tailang M. Swarm Intelligence and Machine Learning Algorithms for Cancer Diagnosis. In Swarm Intelligence and Machine Learning 2022; (pp. 34-50). CRC Press.
23. P. Sharma, V. Jain, and M. Tailang, "Selection and Role of Polymers for Designing of a Drug Carrier", in Drug Carriers [Working Title]. London, United Kingdom: Intech Open, 2022.
24. Pankaj Sharma (August 13th 2021). Applications of Statistical Tools for Optimization and Development of Smart Drug Delivery System [Online First], Intech Open, DOI: 10.5772/intechopen.99632. Available from: https://www.intechopen.com/online-first/78091.
25. Sharma P, Jain V. (2021) Research and Development in Pharmaceutical Science: Surface modified polymeric nanoparticles for enhancing drug delivery of methotrexate in the brain by blocking efflux transporters. Bhumi Publishing, Kolhapur, Maharashtra, India, 1: 01-22.
26. Sharma, P., Akram, W., Jain, V., & Tailang, M. (Eds.). (2024). Smart Nanocarrier for Effective Drug Delivery (1st ed.). CRC Press. https://doi.org/10.1201/9781003438953
27. Bregoli L, Chiarini F, Gambarelli A, et al. Engineered nanoparticles for cancer therapy: a review of recent advances. *Cancers (Basel),* 2023; 15(5): 1512. doi: 10.3390/cancers15051512

28. Batra R, Sharma P, Jain V. (2021) Frontiers-in-Life-Science-Volume-II: Mucormycosis (Black Fungus): Introduction, pathophysiology and its impact on people of Indian Subcontinent. Bhumi Publishing, Kolhapur, Maharashtra, India, 2: 111-18.
29. Batra R, Sharma P, Jain V. (2021) Research and Development in Pharmaceutical Science: Pharmacovigilance: Need, overview and challenges ahead. Bhumi Publishing, Kolhapur, Maharashtra, India, 1: 99-09.
30. Tripathi D, Hajra K, Mulukutla A, Shreshtha R, Maity D. Artificial Intelligence in Biomedical Engineering and Its Influence on Healthcare Structure: Current and Future Prospects. *Bioengineering*, 2025; 12(2): 163. doi: 10.3390/bioengineering12020163
31. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med.*, 2019; 25: 44–56. doi: 10.1038/s41591-018-0300-7
32. Batra R, Sharma P, Jain V. (2021) COVID 19: Impact and Response Volume II: Revisiting health care system in the country and means to improve it: Indian healthcare system in the darkness of COVID-19 pandemic. Bhumi Publishing, Kolhapur, Maharashtra, India, 2: 09-22.
33. Fadeel B, Farcal L, Hardy B, et al. Advanced tools for the safety assessment of nanomaterials. *Nat Nanotechnol.*, 2018; 13(7): 537–43. doi: 10.1038/s41565-018-0185-0
34. Leslie D, Mazumder A, Peppin A, et al. Does AI improve fairness in healthcare? *Lancet Digit Health*, 2021; 3(10): e693–e700. doi: 10.1016/S2589-7500(21)00168-9
35. Tiwari R, Tiwari G, Semwal BC, Amudha S, Soni SL, Rudrangi SR, Chellammal HS, Sharma P. Luteolin-Encapsulated Polymeric Micelles for Anti-inflammatory and Neuroprotective Applications: An In Vivo Study. Bio Nano Science. 2025 Sep; 15(3): 1-22.
36. Tiwari G, Panda S, Diyya A, Thomas NV, Deka T, Rudrangi SR, Patel G, Sharma P. Design and optimization of PLGA-based gemcitabine nanocapsule for enhanced pancreatic cancer efficacy. Investigational New Drugs, 2025 Jul 23; 1-20.
37. Jain D, Sharma P, Jain V. Synergistic evaluation of anti-diabetic and hypolipidemic effects of Alangium salvifolium and Ocimum sanctum extracts. Journal of Biomaterials Science, Polymer Edition, 2025 Jun 30; 1-29.
38. Sharma P, Shivhare P, Jain V. Hydrotropy as a Tool for Enhancing Mefenamic Acid Solubility: A Comprehensive Study. Indian Journal of Pharmaceutical Education and Research, 2025 Feb 4; 59(1s): s52-62.
39. Sharma P, Jain A, Sharma SK, Sharma SK, Parashar A. Selection of Teaching Faculty in Pharmacy/Engineering Institutes by Using an Analytical Hierarchy Process (AHP): A

Procedure Proposed. Indian Journal of Pharmaceutical Education and Research, 2024 Jun 21; 58(3): 940-8.

40. Ojha C, Sharma P*, Jain V. Design, optimization, and evaluation of topical gel of Cardiospermum halicacabum and Ricinus communis L. leaves extract for the treatment of rheumatoid arthritis. Journal of Biomaterials Science, Polymer Edition, 2024 Apr 8; 1-22.
41. Sharma H, Sharma P, Parashar A and Jain V: Formulation and evaluation of *Ficus benghalensis* loaded candy for toothache. Int J Pharm Sci & Res., 2023; 14(11): 5298-05. doi: 10.13040/IJPSR.0975-8232.14(11).5298-05.
42. Sharma P. Validated Ultraviolet Spectrophotometric Method for Simultaneous Estimation of Olmesartan Medoxomil in Marketed Formulation. Asian Journal of Pharmaceutics (AJP), 2023 Sep 15; 17(03).
43. Sharma P. Design, Optimization, and Characterization of Herbal Gel for Facial Application. Asian Journal of Pharmaceutics (AJP), 2023 Sep 15; 17(03).
44. Sharma P, Tailang, M. Primaquine-loaded transdermal patch for treating malaria: design, development, and characterization. *Futur J Pharm Sci* 8, 43 (2022); https://doi.org/10.1186/s43094-022-00433-5
45. Singh F, Sharma P, Jain V, Bhargava S, Phytochemical Screening and Evaluation of Diuretic Activity of Setaria glauca. *International Journal of Pharmaceutical Sciences and Drug Research* (IJPSDR), 2022; 14(5).
46. Sharma P. Modification of Human Behavior due to Coronavirus Outbreak: A Brief Study on Current Scenario. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm., 2021 Nov 1; 15(3).
47. Sharma P, Jain V, Jain S. Fabrication, optimization and evaluation of chronotropic drug deli-very system of captopril. International Journal of Pharmaceutical Sciences and Research, 2021 April 01; 4(12): 1000-08.
48. Sharma P, Tailang M. Design, optimization, and evaluation of hydrogel of primaquine loaded nanoemulsion for malaria therapy. Future Journal of Pharmaceutical Sciences, 2020 Dec; 6(1): 1-1.
49. Sharma P, Tailang M. Design, optimization and evaluation of buccal drug delivery system of propranolol for hypertension treatment. International Journal of Pharmaceutical Sciences and Research, 2020 Jan 11; (1): 301-311.
50. Sharma P, Tailang M. pH Dependent release potential of natural polymers in sustained release of ornidazole from colon targeted delivery system. International Journal of Drug Delivery Technology, 2019 Jan 21; 9(02): 130-7.

51. Sharma P, Tailang M. In-vivo study of orodispersible tablet of primaquine. International Journal of Pharmaceutical Sciences and Research, 2018 Aug 1; 9(8): 3506-10.
52. Sharma P, Bhargava S, Parashar D, Mangal **A.** Formulation and evaluation of nanoparticles containing cyclophosphamide. World Journal of Pharmaceutical Research, 2017 Dec 7; (1): 785-98.
53. Sharma V, Dixit A, Rajput YS, Rathore DS, Joshi R, Sharma P, Parashar D. The analgesic effect of the methanolic extract of sida acuta. Indo American Journal of Pharmaceutical Research, 2015 Sep 5; (09): 2844-48.
54. Rathore DS, Dixit A, Sharma V, Joshi R, Sharma P, Parashar D, Sarvesh, B. Formulation and development of glipizide containing floating microsphere. Indo American Journal of Pharmaceutical Research, 2015 Aug 5(8): 2564-70.
55. Fadeel B, Farcal L, Hardy B, et al. Advanced tools for the safety assessment of nanomaterials. *Nat Nanotechnol.*, 2018; 13(7): 537–43. doi: 10.1038/s41565-018-0185-0
56. Leslie D, Mazumder A, Peppin A, et al. Does AI improve fairness in healthcare? *Lancet Digit Health.*, 2021; 3(10): e693–e700. doi: 10.1016/S2589-7500(21)00168-9
57. S Pankaj, D Ashish, R Dheerendra, R Yogendra, J Ramakant, S Kuldeep. To formulate and evaluate orodispersible tablets of primaquine. Indo American Journal of Pharmaceutical Research, 2015 May 5(5): 1625-32.
58. Dixit A, Jain AK, Sharma N, Saluja GS, Acharya M, Rathore D, Joshi R, Sharma P, Singh Y. Hepatoprotective activity of wrightia tinctoria leaves against d-galactosamine induced hepatotoxicity in rats. Indo American Journal of Pharmaceutical Research, 2015 Jan 5 (1): 422-26.
59. Sharma P, Akram W, Joshi R. Nanotechnology-based implants: recent advances and future prospects for a range of diseases. Journal of Biomaterials Science, Polymer Edition, 2025 Apr 23: 1-26.
60. Ghosh S, Ghosh A, Khan M, et al. Quantum computing in drug discovery and personalized medicine. *Drug Discov Today.*, 2024; 29(4): 103648. doi: 10.1016/j.drudis.2024.103648
61. Chen X, Xu L, Wang X, et al. Wearable nanotechnology for healthcare: Progress and perspectives. *ACS Nano.*, 2021; 15(3): 3949–78. doi: 10.1021/acsnano.0c09185
62. Mundada AB, Pradhan P, Raju R, Sujitha YS, Kulkarni PA, Mundada PA, Tiwari R, Sharma P. Molecular dynamics in pharmaceutical nanotechnology: simulating interactions and advancing applications. Journal of Biomaterials Science, Polymer Edition, 2025 Jan 6: 1-27.

63. Akram W, Joshi R, Haider T, Sharma P, Jain V, Garud N, Narwaria NS. Blockchain technology: A potential tool for the management of pharma supply chain. Research in Social and Administrative Pharmacy. 2024 Feb 23.
64. Sharma P, Jain V. An overview of current advances and pharmaceutical uses of 3D and 4D printing. Explor Med., 2023; 4: 560–75.
65. Batra R, Jain V, Sharma P. Adenosine: a partially discovered medicinal agent. Future Journal of Pharmaceutical Sciences, 2021 Dec; 7(1): 1-0.
66. Sharma P, Tailang M. Opportunities and challenges to develop transdermal patch with nanocarrier. World Journal of Pharmaceutical Research. 2017 Nov 6;(15): 392-00.
67. Sharma P, Tailang M. Role & future aspects of primaquine in malaria therapy, 2016 Aug 5; 11: 573-81.
68. Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, et al. Smart nanoparticles for cancer therapy. *Signal Transduct Target Ther*, 2023; 8: 418. doi: 10.1038/s41392-023-01642-x